Mechanistic target of rapamycin kinase complexes (mTORC1 and mTORC2) (mTORC1/2)

The mechanistic target of rapamycin (mTOR) is a highly conserved serine/threonine protein kinase that functions as a central rheostat for cellular metabolism, growth, and survival (UniProt P42345). It operates within two structurally and functionally distinct complexes: mTORC1, which integrates nutrient and energy sensing to promote protein synthesis and inhibit autophagy, and mTORC2, which regulates the actin cytoskeleton and cell survival through the phosphorylation of Akt (Saxton & Sabatini, Cell 2017). Dysregulation of the mTOR signaling pathway is frequently observed in human malignancies, where it promotes uncontrolled proliferation, as well as in metabolic and neurological disorders (Janku et al., Nature Reviews Clinical Oncology 2018). Pharmacological targeting of these complexes began with rapalogs like sirolimus, which act as allosteric inhibitors primarily of mTORC1, but has evolved to include second-generation ATP-competitive inhibitors that target the catalytic site of both mTORC1 and mTORC2 to prevent compensatory signaling (Mossmann et al., Nature Reviews Drug Discovery 2018). These therapies are widely utilized in oncology, organ transplantation, and the treatment of rare genetic conditions such as Tuberous Sclerosis Complex (StatPearls, mTOR Inhibitors).

Other names

Mammalian target of rapamycinFRAP1RAFT1RAPT1FK506-binding protein 12-rapamycin-associated protein 1

Allosteric inhibition of mTORC1 via FKBP12 binding; ATP-competitive inhibition of the mTOR kinase domain in both mTORC1 and mTORC2 complexes (Mossmann et al., Nature Reviews Drug Discovery 2018).